[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"2e071664-2674-4d6f-b1a9-33056e7adbe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115282","created_at":"2021-01-17T17:34:12.805Z","updated_at":"2025-02-25T16:43:48.211Z","phase":"Phase 3","brief_title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","source_id_and_acronym":"NCT02115282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 03/29/2014","start_date":" 03/29/2014","primary_txt":" Primary completion: 05/05/2020","primary_completion_date":" 05/05/2020","study_txt":" Completion: 06/25/2025","study_completion_date":" 06/25/2025","last_update_posted":"2025-02-06"},{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"1bb717ea-4a5e-4f29-ac5a-fee115e523c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03179930","created_at":"2021-01-18T15:40:48.245Z","updated_at":"2025-02-25T16:06:23.103Z","phase":"Phase 2","brief_title":"Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas","source_id_and_acronym":"NCT03179930","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-01-24"},{"id":"ded04c2b-2ead-4cff-9660-0481bc077bfe","acronym":"MORPHEUS","url":"https://clinicaltrials.gov/study/NCT03280563","created_at":"2021-01-18T16:11:59.285Z","updated_at":"2024-07-02T16:34:37.795Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT03280563 - MORPHEUS","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/26/2017","start_date":" 12/26/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"820e22ed-50fe-40f0-aa7c-051ded02330b","acronym":"CA209-117","url":"https://clinicaltrials.gov/study/NCT01928576","created_at":"2021-01-18T08:42:53.521Z","updated_at":"2025-02-25T14:34:17.894Z","phase":"Phase 2","brief_title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","source_id_and_acronym":"NCT01928576 - CA209-117","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/06/2013","start_date":" 11/06/2013","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-05-03"},{"id":"052ff42c-445e-466e-9061-7503375beb53","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349959","created_at":"2021-01-18T05:30:54.553Z","updated_at":"2024-07-02T16:35:11.296Z","phase":"Phase 2","brief_title":"Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01349959","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/21/2011","start_date":" 04/21/2011","primary_txt":" Primary completion: 03/27/2014","primary_completion_date":" 03/27/2014","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-04-05"},{"id":"80bbead0-defc-4564-bc2a-476e047424b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02936752","created_at":"2021-01-29T07:13:34.466Z","updated_at":"2024-07-02T16:35:13.077Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents","source_id_and_acronym":"NCT02936752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 03/21/2025","study_completion_date":" 03/21/2025","last_update_posted":"2024-03-25"},{"id":"5f31eade-11f2-4c8a-bd77-1e3a256fbe11","acronym":"ETCTN-9844","url":"https://clinicaltrials.gov/study/NCT02453620","created_at":"2021-01-18T11:46:08.614Z","updated_at":"2024-07-02T16:35:13.667Z","phase":"Phase 1","brief_title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02453620 - ETCTN-9844","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD86","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/12/2016","start_date":" 02/12/2016","primary_txt":" Primary completion: 04/22/2021","primary_completion_date":" 04/22/2021","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-20"},{"id":"10e34025-5747-4dee-b161-fb7ad52933b1","acronym":"INFORM2 NivEnt","url":"https://clinicaltrials.gov/study/NCT03838042","created_at":"2021-01-18T18:56:47.273Z","updated_at":"2024-07-02T16:35:20.359Z","phase":"Phase 1/2","brief_title":"INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies","source_id_and_acronym":"NCT03838042 - INFORM2 NivEnt","lead_sponsor":"University Hospital Heidelberg","biomarkers":" PD-L1 • TMB • MYC","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Jingzhuda (entinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 05/26/2020","start_date":" 05/26/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-02-07"},{"id":"fd11a967-714d-4b27-a405-17c45824d40e","acronym":"WOOPS","url":"https://clinicaltrials.gov/study/NCT03978624","created_at":"2021-01-18T19:33:59.403Z","updated_at":"2025-02-25T16:09:11.700Z","phase":"Phase 2","brief_title":"Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer","source_id_and_acronym":"NCT03978624 - WOOPS","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 11/22/2026","study_completion_date":" 11/22/2026","last_update_posted":"2024-02-05"},{"id":"9f5aabcb-abe3-45ce-8ce4-9736a77c00df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02780804","created_at":"2021-01-18T13:38:26.733Z","updated_at":"2024-07-02T16:35:33.366Z","phase":"Phase 1","brief_title":"Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT02780804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/06/2017","start_date":" 01/06/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2023-10-17"},{"id":"b23f772e-d8de-48f2-bd9a-03b0617456c3","acronym":"ENCORE 601","url":"https://clinicaltrials.gov/study/NCT02437136","created_at":"2021-01-18T11:40:17.993Z","updated_at":"2025-02-25T16:14:41.493Z","phase":"Phase 1b/2","brief_title":"Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer","source_id_and_acronym":"NCT02437136 - ENCORE 601","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" PD-L1 • BRAF • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement","tags":["PD-L1 • BRAF • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 09/29/2022","primary_completion_date":" 09/29/2022","study_txt":" Completion: 09/29/2022","study_completion_date":" 09/29/2022","last_update_posted":"2023-09-21"},{"id":"62fa9b0a-5488-474d-9871-bc6f30caf97f","acronym":"Breast 49","url":"https://clinicaltrials.gov/study/NCT03473639","created_at":"2021-01-18T17:07:03.149Z","updated_at":"2024-07-02T16:36:01.464Z","phase":"Phase 1","brief_title":"A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy","source_id_and_acronym":"NCT03473639 - Breast 49","lead_sponsor":"University of Virginia","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 09/02/2021","primary_completion_date":" 09/02/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2022-11-01"},{"id":"601d4e77-5532-49d4-992a-ed4f2529e3dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00828854","created_at":"2022-07-01T17:55:04.307Z","updated_at":"2024-07-02T16:36:08.081Z","phase":"Phase 2","brief_title":"Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing","source_id_and_acronym":"NCT00828854","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 11/24/2009","primary_completion_date":" 11/24/2009","study_txt":" Completion: 11/24/2009","study_completion_date":" 11/24/2009","last_update_posted":"2022-06-30"},{"id":"42cac71f-5d5c-49fa-92a8-b19621381432","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291886","created_at":"2021-01-18T16:15:44.626Z","updated_at":"2024-07-02T16:36:08.536Z","phase":"Phase 2","brief_title":"Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer","source_id_and_acronym":"NCT03291886","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 133","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 03/26/2021","study_completion_date":" 03/26/2021","last_update_posted":"2022-06-21"},{"id":"869cd105-4da3-41c2-9a75-36bbb7499d2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02623751","created_at":"2021-01-18T12:45:00.550Z","updated_at":"2024-07-02T16:36:08.514Z","phase":"Phase 1","brief_title":"Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer","source_id_and_acronym":"NCT02623751","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • exemestane • Lazcluze (lazertinib) • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-21"},{"id":"9f62d2dc-ab6f-4d2c-b13a-56eb05113ed4","acronym":"ENCORE301","url":"https://clinicaltrials.gov/study/NCT00676663","created_at":"2021-01-18T02:31:46.564Z","updated_at":"2024-07-02T16:36:10.649Z","phase":"Phase 2","brief_title":"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer","source_id_and_acronym":"NCT00676663 - ENCORE301","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 130","initiation":"Initiation: 06/13/2008","start_date":" 06/13/2008","primary_txt":" Primary completion: 01/29/2011","primary_completion_date":" 01/29/2011","study_txt":" Completion: 11/26/2012","study_completion_date":" 11/26/2012","last_update_posted":"2022-05-11"},{"id":"44773f2a-aa6e-4eaa-9cde-ee0e44648a12","acronym":"NRG-GY011","url":"https://clinicaltrials.gov/study/NCT03018249","created_at":"2021-01-18T14:51:16.947Z","updated_at":"2024-07-02T16:36:20.688Z","phase":"Phase 1","brief_title":"Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer","source_id_and_acronym":"NCT03018249 - NRG-GY011","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/11/2017","start_date":" 10/11/2017","primary_txt":" Primary completion: 04/18/2018","primary_completion_date":" 04/18/2018","study_txt":" Completion: 03/12/2021","study_completion_date":" 03/12/2021","last_update_posted":"2021-11-16"},{"id":"4ef69d46-6256-4785-8a20-35c99fcc7c78","acronym":"EOC103A3101","url":"https://clinicaltrials.gov/study/NCT03538171","created_at":"2021-01-18T17:26:01.499Z","updated_at":"2024-07-02T16:36:28.136Z","phase":"Phase 3","brief_title":"Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT03538171 - EOC103A3101","lead_sponsor":"Taizhou EOC Pharma Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-07-09"},{"id":"aa2fe266-165a-4ab3-a222-bfe0fccb2cae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01434303","created_at":"2021-01-18T05:55:46.269Z","updated_at":"2024-07-02T16:36:59.460Z","phase":"Phase 1","brief_title":"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only","source_id_and_acronym":"NCT01434303","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • Jingzhuda (entinostat) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/10/2012","start_date":" 01/10/2012","primary_txt":" Primary completion: 02/16/2016","primary_completion_date":" 02/16/2016","study_txt":" Completion: 02/16/2016","study_completion_date":" 02/16/2016","last_update_posted":"2019-05-20"},{"id":"6d94145d-fae9-4788-9b8f-b6dbadbcf58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02833155","created_at":"2021-01-18T13:53:42.103Z","updated_at":"2024-07-02T16:36:59.877Z","phase":"Phase 1","brief_title":"Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT02833155","lead_sponsor":"Taizhou EOC Pharma Co., Ltd.","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/29/2016","start_date":" 08/29/2016","primary_txt":" Primary completion: 07/18/2018","primary_completion_date":" 07/18/2018","study_txt":" Completion: 07/18/2018","study_completion_date":" 07/18/2018","last_update_posted":"2019-05-07"},{"id":"3182f972-65df-4887-8ae2-016eef9a4809","acronym":"","url":"https://clinicaltrials.gov/study/NCT01846897","created_at":"2021-01-18T08:14:24.927Z","updated_at":"2024-07-02T16:37:21.110Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Epigenetic Priming in NSCLC Patients","source_id_and_acronym":"NCT01846897","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • pemetrexed • irinotecan • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-06-14"}]